Methods of Identifying Xenohormetic Phenotypes and Agents

ABSTRACT

Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstuffs under specific conditions of production governed by xenohormetic effects.

CROSS-REFERENCE TO RELATED APPLICATIONS

Pursuant to 35 U.S.C. §119 (e), this application claims priority to thefiling date of U.S. Provisional Patent Application Ser. No. 60847,349filed Sep. 25, 2006; the disclosure of which application is hereinincorporated by reference.

INTRODUCTION

Environmental conditions can have a significant impact on diseaseconditions in an individual. A given individual's disease condition,e.g., obesity, heart disease, diabetes, etc., can be greatly impacted bythe environmental context of the individual. As such, stressesencountered by the individual, both environment and from energy sources,e.g., food, can influence the progression of a given disease conditionin the individual. Because of the significant role environment can playin the progression of a disease condition, there is significant interestin the elucidation of how environment cues, e.g., from energy sources,influence disease.

SUMMARY

Methods of identifying a xenohormetically induced phenotype in anorganism are provided. Also provided are methods of using organismshaving a known xenohormetically induced phenotype in a number ofdifferent applications, such as the identification of xenohormeticagents and the generation of chemical entities and foodstuffs underspecific conditions of production governed by xenohormetic effects.

DETAILED DESCRIPTION

Methods of identifying a xenohormetic induced phenotype in an organismare provided. Also provided are methods of using organisms having aknown xenohormetically induced phenotype in a number of differentapplications, such as the identification of xenohormetic agents and thegeneration of chemical entities and foodstuffs under specific conditionsof production governed by xenohormetic effects.

Before the present invention is described in greater detail, it is to beunderstood that this invention is not limited to particular embodimentsdescribed, as such may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting, since the scope ofthe present invention will be limited only by the appended claims.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges and are also encompassed within the invention, subject toany specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, certainmethods and materials are now described in greater detail forillustrative purposes.

All publications and patents cited in this specification are hereinincorporated by reference as if each individual publication or patentwere specifically and individually indicated to be incorporated byreference and are incorporated herein by reference to disclose anddescribe the methods and/or materials in connection with which thepublications are cited. The citation of any publication is for itsdisclosure prior to the filing date and should not be construed as anadmission that the present invention is not entitled to antedate suchpublication by virtue of prior invention. Further, the dates ofpublication provided may be different from the actual publication dateswhich may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, thesingular forms “a”, “an”, and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

As will be apparent to those of skill in the art upon reading thisdisclosure, each of the individual embodiments described and illustratedherein has discrete components and features which may be readilyseparated from or combined with the features of any of the other severalembodiments without departing from the scope or spirit of the presentinvention. Any recited method can be carried out in the order of eventsrecited or in any other order which is logically possible.

Aspects of the invention include methods of identifying a xenohormeticinduced phenotype in an organism. The term “xenohormesis” as used hereinrefers to the phenomenon by which a stress signal(s) in a first organismis transmitted to a second organism in a process where the secondorganism employs the first organism as an energy source. Wherexenohormesis occurs, the first organism is stressed in some manner,e.g., by caloric intake, substance intake, and/or environment. Thisstress may manifest in a number of different phenotypic ways, rangingfrom outward appearance (e.g., in some way deviating from a normal,wild-type appearance) or in other ways, e.g., by changes in genomicand/or proteomic profiles. Xenohormesis occurs when the second organismthat employs the first organism as food (e.g., by eating the firstorganism) responds in some way to the stress phenotype of the firstorganism, e.g., by adopting a stressed phenotype itself. As such,xenohormesis can result in a stressed phenotype of a first organismbeing transmitted to a second organism when the second organism employsthe first organism as food. Accordingly, the phrase “xenohormeticallyinduced phenotype” refers to the adoption of a stressed phenotype of asecond organism in response to the second organism employing a firststressed organism as food.

The first and second organisms referred to herein may vary considerably,where the term “organism” refers to a live entity that may range in sizeand complexity from single cell entities to complex multicellularspecies. As such, organisms of interest include, but are not limited to:single celled organisms, e.g., multicelled organisms, e.g.,invertebrates and vertebrates, etc. Accordingly, organisms of interestinclude, but are not limited to: prokaryotes, e.g. bacteria, archaea andcyanobacteria; and eukaryotes, e.g. members of the kingdom protista,such as flagellates, amoebas and their relatives, amoeboid parasites,ciliates and the like; members of the kingdom fungi, such as slimemolds, acellular slime molds, cellular slime molds, water molds, truemolds, conjugating fungi, sac fungi, club fungi, imperfect fungi and thelike; plants, such as algae, mosses, liverworts, hornworts, club mosses,horsetails, ferns, gymnosperms and flowering plants, both monocots anddicots; and animals, including sponges, members of the phylum cnidaria,e.g. jelly fish, corals and the like, combjellies, worms, rotifers,roundworms, annelids, molluscs, arthropods, echinoderms, acorn worms,and vertebrates, including reptiles, fishes, birds, snakes, and mammals,e.g. rodents, primates, including humans, and the like.

In the context of the present invention, the first organism serves as anenergy source in some manner for the second organism. As such, thesecond organism views the first organism as a food source and, whenplaced into proximity of the first organism, may employ the firstorganism as a food source, e.g., by eating the first organism. As such,in certain embodiments the first organism is the prey of the secondorganism, such that the first and second organisms have a prey/predatorrelationship. The first organism may or may not be a natural energysource for the second organism, so long as under appropriate conditionsthe second organism will employ the first organism as a food source.

In practicing the subject methods, the first step in certain embodimentsis to provide a stressed first organism. While the stressed firstorganism can be obtained from any convenient source, including acommercial source that sells organisms that are known to be stressed insome manner, in certain embodiments this step includes producing thestressed phenotype in the first organism. The stressed phenotype may beproduced in the first organism using any convenient protocol, where theprotocol employed may include modifying the environment of the firstorganism in some manner sufficient to produce the stressed phenotype inthe first organism. The term “environment” refers broadly to the overallset of conditions in which the first organism is present, includingtemperature, light, energy source availability, etc. As such,environmental modulation can be accomplished in a variety of differentways, including but not limited to: changing the temperature of theorganism, changing the light experienced by the organism, changing thefood intake of the organism, administering a stress inducing agent tothe organism, etc. In certain embodiments, the stressed first organismis produced by changing the nutritional intake of the first organisme.g., by modifying food intake of the organism, such as by restrictingthe caloric intake of the organism, by administering a certain kind ofstress inducing food to the organism, etc. In certain embodiments,producing a stressed phenotype in the first organism includes confirmingthat the first organism has obtained the stressed phenotype of interest,e.g., by comparing the organism to a control or reference. As reviewedabove, the stressed phenotype that is produced may vary greatly, e.g.,from appearance (e.g., skinny) to behavior to certain stressed genomicand/or proteomic profiles.

Upon provision of the first organism having a known stressed phenotype,the first organism is then fed, e.g., by placing the first organism inthe vicinity of the second organism, to the second organism. In thesubject assay methods, the first organism is brought into contact withone or more of, e.g., a population of, the second organism in a mannersuch that the second organism can feed on the first organism. In certainembodiments, the first organism is brought into contact with the secondorganism in a manner such that the second organism can internalize bythe first organism. e.g., feed on the first organism. In certainembodiments, internalization will be by ingestion, i.e. orally, suchthat that the first organism is contacted with the second organism byincorporating the first organism in a nutrient medium, e.g. water,aqueous solution of additional nutrient agents, etc., of the secondorganisms. As such, in this step of embodiments of the invention, thestressed first organism is fed to the second organism.

Following feeding of the stressed first organism to the second organism,the second organism is evaluated to identify the presence of axenohormetically induced phenotype. The evaluation may occur immediatelyafter feeding or at some time after feeding, e.g., about 5 minutes orlonger after feeding, about 10 minutes or longer after feeding, about 30minutes or longer after feeding, about 1 hour or longer after feeding,about 6 hours or longer after feeding, about 12 hours or longer afterfeeding, about 1 day or longer after feeding, about 1 week or longerafter feed, etc., depending at least in part on the nature of the firstand second organisms. Evaluation may include a single assessment ormultiple assessments of the second organism over a given period of timefollowing feeding.

In evaluating the second organism for a xenohormetically inducedphenotype, the second organism is assessed for the presence of astressed phenotype that has been caused by feeding on the stressed firstorganism. As above, the stressed phenotype for which the second organismis evaluated may be a number of different types of phenotypes, includingbut not limited to: appearance to behavior to certain stressed genomicand/or proteomic profiles. As such, evaluation of the second organismmay include visual assessment of outward phenotypic characteristics,such as visual inspection of the appearance of the second organism,e.g., to determine the presence of stress by identifying the presence ofone or more stress correlated appearance characteristics. Evaluation ofthe second organism may, in certain embodiments, include behavioralassessment of the second organism, e.g., to determine the presence ofstress by identifying one or more stress correlated behavioralcharacteristics. Evaluation of the second organism may, in certainembodiments, include genomic assessment of the second organism, e.g., todetermine the presence of stress by identifying one or more stresscorrelated gene expression characteristics (as may be readily identifiedby gene expression analysis). Evaluation of the second organism may, incertain embodiments, include proteomic assessment of the secondorganism, e.g., to determine the presence of stress by identifying oneor more stress correlated behavioral characteristics (as may be readilyidentified using protein expression analysis). In certain embodiments,this evaluation step includes comparison of the second organism to acontrol or reference organism known not be stressed.

This evaluation step results in the identification of whether the secondorganism is or is not stressed. Upon comparison to an appropriatecontrol, the presence of the stressed phenotype can be attributed to thesecond organism employing the first organism as an energy source, e.g.,by feeding on the first organism. In these situations, the presence ofthe stressed phenotype in the second organism can be identified as axenohormetically induced phenotype. In this manner, the methods of theinvention provide a way to identify the presence of a xenohormeticallyinduced phenotype in the second organism.

In certain embodiments, the methods include identifying the firstorganism as a xenohormetic organism. By “xenohormetic organism” is meantan organism that induces a stress phenotype on a second organism uponbeing employed by the second organism as an energy source, e.g., uponbeing eaten by the second organism. As such, xenohormetic organisms areorganisms that transmit a stressed phenotype to organisms that employthem in some manner as a source of nutrition.

Embodiments of the invention include methods of screening a candidatecompound for xenohormetic activity. By “screening” is meant assessing orevaluating an agent for its ability to modulate (i.e., change) aphenotype in an organism in a xenohormetic fashion. As such, methodsinclude identifying whether an agent enhances or reduces, includinginhibits, a xenohormetically induced phenotype in an organism. Inpracticing these embodiments of the invention, the methods may includecontacting a candidate compound with an organism exhibiting a knownxenohormetically induced phenotype (such as an organism identified asdescribed above); and evaluating the organism to determine any change inthe xenohormetically induced phenotype to identify the compound forxenohormetic activity.

The candidate agent may be contacted with the organism using anyconvenient protocol, e.g., by placing the agent in the nutrient mediumof the organism, by administering the agent to the organism, etc. Alarge number of different types of compounds may be evaluated forxenohormetic activity. Compounds that may be evaluated encompassnumerous chemical classes, though typically they are organic molecules,preferably small organic compounds having a molecular weight of morethan 50 and less than about 2,500 daltons. Compounds may includefunctional groups necessary for structural interaction with proteins,particularly hydrogen bonding, and may include at least an amine,carbonyl, hydroxyl or carboxyl group, such as at least two of thefunctional chemical groups. The compounds may include cyclical carbon orheterocyclic structures and/or aromatic or polyaromatic structuressubstituted with one or more of the above functional groups. Compoundsof interest are also found among biomolecules including, but not limitedto: peptides, saccharides, fatty acids, steroids, purines, pyrimidines,derivatives, structural analogs or combinations thereof.

Compounds of interest may be obtained from a wide variety of sourcesincluding libraries of synthetic or natural compounds. For example,numerous means are available for random and directed synthesis of a widevariety of organic compounds and biomolecules, including expression ofrandomized oligonucleotides and oligopeptides. Alternatively, librariesof natural compounds in the form of bacterial, fungal, plant and animalextracts are available or readily produced. Additionally, natural orsynthetically produced libraries and compounds are readily modifiedthrough conventional chemical, physical and biochemical means, and maybe used to produce combinatorial libraries. Known pharmacological agentsmay be subjected to directed or random chemical modifications, such asacylation, alkylation, esterification, amidification, etc. to producestructural analogs. New potential agents may also be created usingmethods such as rational drug design or computer modeling.

Following contact of the compound composition with the organism, theeffect of the compound on the organism is determined. The effect of thecompound on the organism may be determined by evaluating one or more ofa number of different phenotypic parameters. Phenotypic parameters thatare evaluated in a given assay of the subject invention may vary widelydepending, at least in part, on the nature of the multi-cellularorganisms being employed. Phenotypic parameters that may be evaluated inany given assay include one or more of the following: (1) viability; (2)morphological defects; and (3) fecundity. Specific parameters that maybe evaluated include one or more of: (1) lethal dose, e.g. LD50, LD10etc.); (2) growth defects; (3) sterility effect dose; (4) developmentaldefects; (5) neurologic impairment; (6) life-span modulation, e.g. lifespan enhancing or shortening; and the like. Of particular interest incertain embodiments is the assessment of whether the organism hasreverted to a non-stressed state.

In addition to the above parameters that can be evaluated in the subjectmethods, the gene expression levels of the test organisms can beassayed, e.g. gene expression levels in treated larva, pupa, and/orflies can be evaluated. The genes can be from “houskeeping” genes thatprovide basic metabolic information to developmental and tissue specificgenes to gauge which tissue or cell type is affected and when. A varietyof different gene expression protocols, including arrays basedprotocols, are known to those of skill in the art, including thosedescribed in: EP 0 328 829 B1 and U.S. Pat. Nos. 5,468,613; 5,580,726;5,599,672; 5,512,462; 5,162,209 and 5,162,209, the disclosures of whichare herein incorporated by reference. Methods of analyzing differentialgene expression are also described in Maniatis, et al., MolecularCloning, A Laboratory Manual, (Cold Spring Harbor Press, Cold SpringHarbor, N.Y.) (1989); Nucleic Acid Hybridization, A Practical Approach(Hames, B. D., and Higgins, S. J. eds, IRL Press, Oxford) (1985); WO95/21944; Chalifour, et al., Anal. Biochem. (1994) 216: 299 304; Nguyenet al., Genomics (1995) 29: 207 216; Pietu et al., Genome Res. (1996) 6:492 503; and Zhao et al., Gene (1995) 166: 207 213.

Patents and patent applications describing methods of genomic expressionanalysis include, but are not limited to: U.S. Pat. Nos. 5,143,854;5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980;5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,800,992. Alsoof interest are U.S. Pat. Nos. 6,656,740; 6,613,893; 6,599,693;6,589,739; 6,587,579; 6,420,180; 6,387,636; 6,309,875; 6,232,072;6,221,653; and 6,180,351.

Also of interest are proteomic analysis assays, e.g., where arrays ofpolypeptide binding agents are employed. Where the arrays are arrays ofpolypeptide binding agents, e.g., protein arrays, specific applicationsof interest include analyte detection/proteomics applications, includingthose described in U.S. Pat. Nos. 4,591,570; 5,171,695; 5,436,170;5,486,452; 5,532,128 and 6,197,599 as well as published PCT applicationNos. WO 99/39210; WO 00/04832; WO 00/04389; WO 00/04390; WO 00/54046; WO00/63701; WO 01/14425 and WO 01/40803—the disclosures of which areherein incorporated by reference.

The effect of the compound on the particular physical parameter orparameters being evaluated may be determined manually or robotically,such that in many embodiments determination of the effect of thecompound on the organism is accomplished via an automated procedure.

The effect of the compound on the phenotypic parameter or parameters isthen related to the xenohormetic activity of the compound. As such, theeffect on the phenotypic parameter(s) is employed to derive axenohormetic activity assessment for the assayed compound.

Also provided are methods of using organisms having knownxenohormetically induced phenotypes to produce a product. By knownxenohormetically induced phenotype is meant that the xenohormetic stateof the organism is predetermined. As such, in some way thexenohormetically induced condition of the organism has been evaluatedand is known. Xenohormetically induced condition may include thepresence or absence of a stress phenotype, such that a knownxenohormetically induced phenotype can refers organisms that have knownstressed phenotype that has been acquired from feeding on anotherorganism and to organisms that are known not to have a stressedphenotype that has been acquired by feeding on another stressedorganism.

Producing a product refers broadly to the procedure of using an organismto produce any kind of product, where the product may vary greatly fromtherapeutic products to nutritional products. As such, methods of theinvention include employing organisms known to be not xenohormetic toproduce nutritional products, e.g., food. In certain embodiments, theproduct comprises a protein, e.g., is a meat product, milk, eggs, etc.,that is harvested from the organism as food.

In certain embodiments, the organism is known to not have a stressedphenotype because it is an organism that has been administered asufficient amount of an antixenohormetic agent, e.g., an agentidentified using the screening protocols described above.

Aspects of the invention further include methods of identifying axenohormetic agent. In practicing these embodiments of the invention,the first step may include identifying a first organism that is capableof transmitting a stress phenotype to a second organism, such that thefirst organism may be viewed as a xenohormetic organism. While suchorganisms may be identified using any convenient protocol, in certainembodiments this step includes practicing the methods described above toobtain an organism known to be xenohormetic, e.g., that can induce astressed phenotype on a second organism upon its use as food by thesecond organism.

Once the xenohormetic organism is identified, the organism is screenedto identify the presence of one or more candidate agents to inducexenohormesis. The organism may be screened in this step using anyconvenient protocol, where the nature of the screen or assay (i.e.,testing protocol) will be chosen at least in part on the nature of thecandidate agent to be determined. For example, in certain embodimentsthe candidate agent(s) to be identified is a protein. Proteinaceouscandidate agents may be identified in a number of different ways.Identification protocols of interest include, but are not limited to:genomic protocols, proteomic protocols, etc. For example, the geneexpression profile of an organism may be evaluated to identify genesthat are differentially expressed between xenohormetic and normalorganisms, where the differentially expressed nucleic acids may betested themselves as candidate agents or the protein produces encoded bythe differentially expressed nucleic acids may be tested as candidateagents. Any convenient differential gene expression protocol may beemployed, where representative protocols of interest include, but arenot limited to those described in U.S. Pat. Nos. 5,143,854; 5,288,644;5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270;5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,800,992. Also of interestare U.S. Pat. Nos. 6,656,740; 6,613,893; 6,599,693; 6,589,739;6,587,579; 6,420,180; 6,387,636; 6,309,875; 6,232,072; 6,221,653; and6,180,351.

Alternatively, the proteome of the organism may be evaluated to identifycandidate agents to induce xenohormesis. Proteomic evaluation protocolsof interest include, but are not limited to those described in U.S. Pat.Nos. 4,591,570; 5,171,695; 5,436,170; 5,486,452; 5,532,128 and 6,197,599as well as published PCT application Nos. WO 99/39210; WO 00/04832; WO00/04389; WO 00/04390; WO 00/54046; WO 00/63701; WO 01/14425 and WO01/40803—the disclosures of which are herein incorporated by reference.

Following identification of one or more candidate agents, the candidateagents are evaluated for their ability to induce xenohormesis. This stepmay include contacting one or more candidate agents with a test organismto determine whether the agent can induce a stress phenotype in the testorganism. Any convenient protocol for contacting and evaluating may beemployed, such as those described above.

The following examples are offered by way of illustration and not by wayof limitation.

EXPERIMENTAL

-   1. Screening for xenohormetic compounds: E. coli, C. elegans, and    longevity/reproductive sterility.

Caenorhabditis elegans N2 variety Bristol is used for screening, and isinitially maintained on NGM agar using standard techniques. NGM platesare prepared with the addition of substances to be screened in thepresence of 0.1% tergitol (NP-40). E. coli strain OP50 is grown on theplates for 2-3 days at room temperature before the addition of embryosor larvae. At various timepoints following initial incubation, sterilityis scored by examining animals under a stereo dissecting microscope forthe presence or absence of embryos in the uterus. Unless otherwisenoted, 100 animals were scored for each fatty acid treatment. Afterscoring for sterility, the entire population from the plate (200-300animals) is washed off the plate. To assess viability, SYTO 12 stainingof apoptotic corpses is performed. Diamindinophenylindole (DAPI)staining is also performed using the method described, and the DAPIstained samples are mounted in Vectashield and examined by fluorescencemicroscopy and Nomarski optics. This method enables identification ofparticular substances whose effects on inducing stress in the primarydiet of C. elegans, E. coli, yielded increased/decreased C. eleganssterility and longevity and thereby suggests the induction ofxenohormesis. Such substances can then be deployed in batch productiongene expression systems to yield particular profiles of compoundsproduced in conjunction with a predefined desired level of stress.

2. Production of xenohormetic foodstuffs: chicken eggs.

Egg laying hens are allocated to groups raised under different ambientconditions (lighting, temperature) and administered different diets forfour weeks. Eggs produced during this time are ingested by humansubjects—on each day, each subject ingested a particular type of egg.Over the 24 hours following ingestion of each type of egg, cortisollevels and heart rate variability are measured as proxies for level ofstress incurred with ingestion, enabling identification of specificconditions or substances that yielded the production of eggs thatconsistently either promoted or relieved stress.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it is readily apparent to those of ordinary skill in theart in light of the teachings of this invention that certain changes andmodifications may be made thereto without departing from the spirit orscope of the appended claims.

Accordingly, the preceding merely illustrates the principles of theinvention. It will be appreciated that those skilled in the art will beable to devise various arrangements which, although not explicitlydescribed or shown herein, embody the principles of the invention andare included within its spirit and scope. Furthermore, all examples andconditional language recited herein are principally intended to aid thereader in understanding the principles of the invention and the conceptscontributed by the inventors to furthering the art, and are to beconstrued as being without limitation to such specifically recitedexamples and conditions. Moreover, all statements herein recitingprinciples, aspects, and embodiments of the invention as well asspecific examples thereof, are intended to encompass both structural andfunctional equivalents thereof. Additionally, it is intended that suchequivalents include both currently known equivalents and equivalentsdeveloped in the future, i.e., any elements developed that perform thesame function, regardless of structure. The scope of the presentinvention, therefore, is not intended to be limited to the exemplaryembodiments shown and described herein. Rather, the scope and spirit ofpresent invention is embodied by the appended claims.

1-8. (canceled)
 9. A method of screening a candidate compound forxenohormetic activity, said method comprising: a) contacting saidcandidate compound with an organism; and b) evaluating said organism todetermine any change in said phenotype to screen said compound forxenohormetic activity.
 10. The method according to claim 9, wherein saidorganism exhibits a stressed phenotype caused by employing a stressedorganism as nutritional source and said method comprises identifyingsaid compound as having antixenohormetic activity if said change in saidorganism occurs so that said organism exhibits a non-stressed phenotypefollowing contact with said candidate agent.
 11. The method according toclaim 9, wherein said candidate agent is a small organic compound. 12.The method according to claim 9, wherein said candidate agent is apeptide.
 13. The method according to claim 12, wherein said peptide is aprotein.
 14. A method comprising employing an organism having a knownxenohormetically induced phenotype as to produce a product.
 15. Themethod according to claim 14, wherein said product is a nutritionalproduct that is harvested from said organism.
 16. The method accordingto claim 15, wherein said nutritional product comprises a protein. 17.The method according to claim 16, wherein said nutritional product ismeat.
 18. The method according to claim 16, wherein said nutritionalproduct is milk.
 19. The method according to claim 15, wherein saidnutritional product is an egg.
 20. The method according to claim 14,wherein said organism has been administered an xenohormetic agent toreduce stress.
 21. A method of identifying a xenohormetic agent, saidmethod comprising: a) identifying a first organism as a xenohormeticorganism; b) screening the proteome of said first organism for one ormore candidate xenohormetic agents; c) contacting said one or morecandidate xenohormetic agents with a test organism to determine whethersaid agent is a xenohormetic agent.